ISSN: 2520-5234

Available online at http://www.sjomr.org

SCIENTIFIC JOURNAL
OF MEDICAL RESEARCH

Vol. 3, Issue 11, pp 95-100, Summer 2019

ORIGINAL ARTICLE

A Comparison between The Topical and Intravenous Administration of Lignocaine to Aid The Insertion of Laryngeal Mask Airway

Saad A. Hussein [1] , **Radhwan H. Alkhashab** [2] **and Ali J. Ali** [3]

[1,2] Anesthesia and Critical Care Department, Aljamhory Teaching Hospital, Mosul, Iraq.
[3] Department of General Surgery, Aljamhory Teaching Hospital, Mosul, Iraq.

ARTICLE INFORMATIONS

Article History:
Submitted: 14 June 2019
Revised version received:
22 July 2019
Accepted: 17 July 2019
Published online: 1 September 2019

Key words:
Laryngeal mask airway
Cough reflex
Laryngeal spasm

Corresponding author:
Ali J. Ali
Email: alijumaaali15699@gmail.com
Department of General Surgery
Aljamhory Teaching Hospital
Mosul
Iraq

ABSTRACT

Objectives: The cough reflex and laryngeal spasm & cardiovascular hazards were significant after the insertion of laryngeal mask airway. Aim of the study to determine the proper way to aid the insertion of Laryngeal mask airway.

Methods: The study was performed between December 2007 and December 2008 in Al jumhori teaching hospital.

Results: Cough and laryngeal spasm due to the insertion of LMA (Laryngeal mask airway) were statistically significant in a group A (control group), but cough and laryngeal spasm in a group B (lignocaine I.V.) ,is statistically not significant, and in a group C (the topical lignocaine) showed no cough and no laryngeal spasm.

Conclusion: the use of topical lignocaine spray is the best aid for the insertion of LMA.

Citation: Hussein S.A., Alkhashab R.H. and Ali A.J. "A Comparison between The Topical and Intravenous Administration of Lignocaine to Aid The Insertion of Laryngeal Mask Airway". Sci. J. Med. Res. 2019; 3 (11): 95-100.

INTRODUCTION

Laryngeal spasm is a very primitive reflex and is intended to protect the lungs from inhalation of noxious substances due to sensory stimulation of superior laryngeal nerve [1].

Laryngeal spasm may be precipitated by surgical and visceral stimulation such as incision, peritoneal traction, anal stretch and cervical dilatation ((or the presence of secretions, blood or foreign bodies)) e. g: An oropharyngeal airway or laryngeal mask airway in the region of the pharynx and larynx, mainly occur during light anesthesia. Children are particularly more prone to laryngeal spasm than adults [1]. Therefore, laryngospasm is most common during induction and emergence from general anaesthesia [1]. Cardio vascular response to laryngoscopy, intubation, insertion of laryngeal mask airway and insertion of Guedel airway arranged according to the severity of the response. Causes hypertension, tachycardia and arrhythmias [2]. The deflated cuff laryngeal mask airway is lubricated and inserted blindly in to the hypopharynx but LMA insertion under direct visualization with a laryngoscope or fibro optic bronchoscope may prove beneficial in difficult cases [3].

Treatment of laryngeal spasm includes:

Providing gentle positive pressure ventilation with 100% oxygen or administering i.v. lignocaine (1-1.5mg / kg) if

laryngeal spasm persists and hypoxia develops succinylcholine (0.25-1 mg /kg) should be given in order to paralyze the laryngeal muscles and allow controlled ventilation [3].

The stimulation of laryngeal mask to the upper airways is not severing like laryngoscopy and intubation so the cardio vascular response is much less. When we use lignocaine i.v. there will be cardio vascular stability, so the response will be less, on the other hand ,the use of lignocaine spray in enough doses will abolish, the cardio vascular response completely to the insertion of the laryngeal mask airway. The Cardio vascular response occurs during light general anesthesia, hypoxia, hypercapnia or cough can cause this reflex in group A, of patients because of the stimulation of nerve endings of vagus and trigeminal nerves [4,5] and the sympathoadrenal response [5].

The Consequent rise in rate — pressure product may result in myocardial oxygen demand which exceeds the oxygen supply and under these circumstances, may induce myocardial ischemia [6]. An increase in heart rate is more likely than hypertension to produce signs of myocardial ischemia on the ECG [7]. Indeed, in an anaesthetized patient the incidence of myocardial ischemia sharply increases in patients who experiences heart rate greater than 110 beats/min. ((Ischemic threshold)) [7]. When heart rate is less than 110 beats/min. The incidence of myocardial ischemia is random and silent being unrelated to heart rate [7].

Conceptually, the rapid heart rate increases the myocardial oxygen requirements and decreases the time during diastole for coronary blood flow and thus delivery of oxygen. Conversely, increased myocardial oxygen requirements produced by hypertension tend to be off set by improved perfusion through pressure dependent atherosclerotic coronary arteries [7]. In healthy patients, these responses are generally well tolerated. However, In patients with limited coronary or myocardial reserve, myocardial ischemia or failure may follow. The patients with vascular lesion at risk such as intracranial vascular anomaly or trauma of the thoracic aorta may also suffer a serious sequel [2]. This response is sympathetically mediated [6,8,9,10,11].

Lignocaine was synthesized in 1943 in Sweden, by Lofgren of AB Astra and it was introduced in to clinical practice in 1948 [12]. (Figure 1).



Figure 1: **The structure of lignocaine**

Mechanism of action

It has quinidine like action (a cell membrane stabilizing effect) which causes:

1- Reduce automaticity of pacemaker cells: suppress premature beats or an ectopic pacemaker.
2- Reduce responsiveness of cardiac cells to excitation.
3- Reduce conduction velocity of an impulse, both 2&3 of help to limit the speed of abnormal impulse. In normal therapeutic doses there is no change in myocardial pump action [13].

It does not alter the PR, QRS or QT intervals on ECG and has minimal negative inotropic effect. An excessive plasma concentration may decrease the conduction of cardiac impulse through the AV node and His - Purkinje system, and evoke seizures followed by coma. Large doses (5 mg / kg) administered to animal my increase the intensity and duration of neuromuscular blockade produced by non - depolarizing muscle relaxants

Mode of action of lignocaine as a local anaesthetic

Three distinct sites have been proposed where local anaesthetic might exert their effect on Sodium conductance across the nerve membrane these are:

- On the membrane surface involving alteration of the fixed negative charge and hence trans membrane potential without change in resting intra cellular potential.
- Within the membrane matrix, involving its lateral expansion. There by causing distortion of the sodium channel.
- Specific receptors within the sodium channel.

Half life: After single i.v. injection, the plasma concentration declines in two phases: the first is rapid (8 min), and reflects dilution of the drug in the blood and distribution to tissue with rapid blood flow within half an hour the rate of fall in plasma concentration change to a second phase (90-100min) which reflects removal of the drug from the circulation by metabolism.

Dose and route of administration:

- **Loading dose:** is 1-2 mg / kg as an i.v. bolus, followed by infusion for 12-48 hours, at a rate of 4 mg / min. for 30 min., 2 mg / min. for the next 2hrs. And then at 1 mg / min. For treatment of ventricular ectopic.
- **Through endotracheal tube to got a systemic effect.**
- **Oral:** it has high hepatic first pass metabolism, require too frequent dosing to be practicable.
- **Topical:** Due to its high lipid solubility and the rapid route of absorption, therapeutic plasma concentration may occur following laryngeal spray [14], peritoneal dialysis, after topical application to the epicardium during open heart surgery and following subcutaneous infiltration during neurosurgery [14].

Metabolism: Lidocaine is rapidly eliminated by hepatic metabolism. The liver metabolizes 70% of the lidocaine

that enters the hepatic circulation at any given moment [15]. The resulting metabolites monoethylglycin exylidide (MEGX) and glycinxilldine (GX) still have pharmacological activity and may contribute to the CNS toxicity [12].

Clinical uses:

- As a local anaesthetic agent.
- Treatment of ventricular premature beats [7].
- Treatment of recurrent ventricular fibrillation [7].
- To prevent reflexes by giving 1-1.5 mg /kg 4 min. before laryngoscopy.

Adverse effects:

- Drowsiness, convulsion and coma.
- In very large doses AV conduction depression and the negative inotropic effect.
- On neuromuscular transmission, depress ganglionic transmission and neuromuscular transmission; enhance the action of neuromuscular blocking agent.

Systemic toxicity from local administration causes, with increasing plasma concentration, sedation, anxiety, restlessness, tremors, parasthesia severe hypoxia and acidosis which can occur compound the drug - induced medullary depression and aggravate depressed myocardial function, so that profound cardio vascular collapse ensures toxicity appears with decreased hepatic blood flow as occurs with reduced cardiac output.

MATERIALS AND METHODS

Sixty patients were selected, following the selection criteria below, divided into equal groups, each group of 20 patients:

1. Group A: control group (not given any drug) and the insertion of LMA after 5 minutes from induction.
2. Group B: lignocaine group (use lignocaine 1 mg / kg), slow i.v. injection immediately before induction and 5 minutes before the insertion of LMA.
3. Group C: given topical lignocaine spray 10% 40 mg to the larynx and the posterior pharyngeal wall before induction and 5 minutes before the insertion of LMA.

Selection criteria:

1- All patients were adult males, any patients below 18 years or above 45 years of age were excluded.
2- All patients were of class 1 - ASA, of average weight and height.
3- Only patients with peripheral surgery were included (relatively short operations not need muscle relaxants. The upper and lower limb surgery, varicocele perianal abscess).
4- Any patient with temporomandibular joint dysfunction, pharyngeal obstruction and pathology like: pharyngeal abscess was excluded because it needs to open the mouth widely enough to insert the LMA.
5- Any case of full stomach was excluded from the study.

Method: The patients were not premedicated. Induction of anaesthesia by thiopentone sodium 6 mg / kg , most of the patients needed manual assisted ventilation because of the apnea of thiopentone until the return of the spontaneous breathing. The maintenance of anaesthesia by halothane 3%, l00% oxygen. After 5 minutes from induction. Insertion of LMA size 3 were made in all cases. All patients monitored which include ECG (Lead II), noninvasive blood pressure (NIB) and pulse oximetry. Any case with difficult insertion of LMA or need laryngoscopy for insertion of LMA was excluded from the study. The Observation of cough, laryngeal spasm during insertion of LMA. Heart rate and mean blood pressure (MBP) readings taken at pre induction, after insertion of LMA and after 3 minutes from insertion of LMA.

RESULTS

The three groups were comparable in age, weight, heart rate and mean blood pressure.

Cough and laryngeal spasm due to insertion of LMA were statistically significant in group -A- (control group) by using Z test; P value < 0.05, but cough and laryngeal spasm in group -B- (Lignocaine i.v.) is statistically not significant P value > 0.05, and in group -C- (topical lignocaine) there were no cough and no laryngeal spasm. Mean blood pressure (MBP) and heart rate (H.R) pre induction considered as the base line values. After insertion of LMA the mean blood pressure and heart rate statistically significantly increased for a group -A- and group -B- (by using paired t. test); P value < 0.05, but in group -C-: mean blood pressure and heart rate statistically not significantly increased, P value > 0.05. By using the student's t. test.

When comparison of the increase in mean blood pressure and heart rate among the three groups, there were no significant difference between lignocaine i.v. and control groups; P value > 0.05 also there were no significant difference between topical lignocaine & control group, P value > 0.05 and no significant difference between topical and i.v. lignocaine; P value > 0.05. (Tables 1 , 2 and 3).

Table 1: **Data of patient in control group (not given any drug).**

No.	L.Spasm	Cough	Pre induction		After insertion of LMA		After 3 min.	
			Heart rate	MBP	Heart rate	MBP	Heart rate	MBP
1	+	-	90	93	62	110	85	110
2	+	-	82	95	110	113	102	108
3	-	-	95	102	116	107	110	100
4	-	+	70	83	113	99	107	102
5	-	-	85	76	100	82	90	85
6	-	-	88	80	122	90	115	85
7	+	-	105	84	81	115	86	115
8	-	+	105	84	81	115	86	115
9	+	-	92	98	106	101	90	93
10	-	-	86	91	107	85	102	85
11	-	+	80	105	97	98	97	98
12	-	-	75	97	90	110	85	107
13	-	-	85	89	102	93	98	93
14	-	-	93	86	110	97	95	95
15	-	+	99	78	125	95	115	93
16	-	-	110	75	123	82	118	82
17	-	+	91	105	115	115	110	115
18	-	-	75	93	95	104	95	104
19	-	-	84	80	99	92	95	93
20	-	-	78	95	92	109	90	110
Mean	4	5	88	89	105	100	100	99
SD	*		10	10	16	11	11	11

The percentage of laryngeal spasm 20%, cough 25 %
The percentage of increase after insertion of LMA from the base line are: Mean blood pressure 12 % , Heart rates 18.9 % , SD= Standard deviation
The laryngeal spasm in 3 patients ended by the injection of 25 mg of succinylcholine and the other patients ended within 90 sec. After providing positive pressure ventilation.
The ventricular ectopic beats where developed in three patients which ended spontaneously after the proper positioning of the LMA.

Table 2: **Data of patient in lignocaine group (use lignocaine 1 mg / kg).**

No.	L.Spasm	Cough	Pre induction		After insertion of LMA		After 3 min.	
			Heart rate	MBP	Heart rate	MBP	Heart rate	MBP
1	-	-	92	84	105	90	100	93
2	-	-	72	102	85	110	92	105
3	-	-	85	105	102	100	97	92
4	-	-	83	98	90	108	95	105
5	-	-	90	110	85	103	90	100
6	-	+	97	85	110	112	105	105
7	-	-	105	90	108	95	108	95
8	-	-	97	83	95	88	90	85
9	-	-	88	92	93	95	95	92
10	-	-	93	105	98	115	100	110
11	-	+	78	107	92	110	92	115
12	-	-	81	97	85	93	90	93
13	-	-	87	93	93	91	92	90
14	-	-	85	98	100	102	95	100
15	-	-	110	103	105	107	105	107
16	-	-	94	100	97	97	97	96
17	-	-	86	92	96	102	88	101
18	-	-	102	87	112	92	110	93
19	-	-	107	93	105	106	105	102
20	-	-	100	101	115	92	108	92
Mean	0	2	92	96	98	101	98	99
SD	*		10	8	9	9	7	8

The percentage of laryngeal spasm 0, cough 10 %
The percentage of increase in: Mean blood pressure 5 % , Heart rate 7%.

Table 3: **Data of patient in given topical lignocaine spray 10% 40 mg to the larynx and the posterior pharyngeal wall before induction and 5 minutes before the insertion of LMA.**

No.	L.Spasm	Cough	Pre induction		After insertion of LMA		After 3 min.	
			Heart rate	MBP	Heart rate	MBP	Heart rate	MBP
1	-	-	75	82	83	86	85	90
2	-	-	87	93	96	95	95	87
3	-	-	85	94	103	93	102	92
4	-	-	92	97	98	101	98	101
5	-	-	105	110	115	102	110	96
6	-	-	90	102	85	105	85	103
7	-	-	98	105	95	103	96	105
8	-	-	102	111	105	113	105	108
9	-	-	110	120	107	112	100	101
10	-	-	70	85	88	93	90	95
11	-	-	83	92	97	95	94	93
12	-	-	115	122	104	112	102	110
13	-	-	97	108	108	102	105	103
14	-	-	102	105	95	113	92	91
15	-	-	120	104	110	106	110	105
16	-	-	85	93	77	98	80	96
17	-	-	84	101	91	106	93	104
18	-	-	92	85	99	97	97	97
19	-	-	99	92	92	98	90	85
20	-	-	105	91	110	96	108	98
Mean	0	0	95	100	98	101	97	98
SD			13	11	10	8	9	7

There are no cough and no laryngeal spasm in this group.
The percentage of increase in: Heart rate 3 % , Mean blood pressure 1.3 %.

DISCUSSION

Our objective in this study is to find the effective drug or route of the administration of lignocaine to reduce the incidence and severity of cough, laryngeal spasm and cardiovascular response to the insertion of LMA during thiopentone anesthesia. The respiratory tract is hypersensitive to stimuli arising during light thiopentone anaesthesia [4]. Laryngeal spasm is a forceful involuntary spasm of laryngeal musculature caused by a sensory stimulation of the superior laryngeal nerve [3]. Lignocaine spray in enough doses can cause adequate surface anaesthesia to the larynx and pharynx providing a high level of stabilization of the cell membrane of laryngeal and pharyngeal musculature and eliminating its sensitivity to stimulation due to the insertion of LMA , but lignocaine i.v. can cause stabilization of cell membrane of nerves of larynx and pharynx decreasing their sensitivity to stimulation by LMA , but to a degree less than lignocaine spray, depending on the dose of lignocaine i.v. (the higher the dose the higher degree of stabilization).

CONCLUSIONS AND RECOMMENDATIONS

- Insertion of laryngeal mask requires depth of anaesthesia less than that with laryngoscopy and intubation, but a greater depth of anaesthesia than the insertion of guedel airway.
- The incidence of cough reflex and the laryngeal spasm is significant in the control group and less significant in lignocaine i.v. and neither cough nor spasm in topical lignocaine.
- There were no significant differences in cardio vascular response between the three groups.
- Providing good depth of anaesthesia the cardio vascular response to the insertion of laryngeal mask airway will be minimal with the use of lignocaine.

Regarding the cough & laryngeal spasm, the use of topical lignocaine spray is the best aid for the insertion of LMA.

REFERENCES

1. Aitken head A.R. and Smith G. "Text blood of an aesthesia". 2013; Pp. 3, 143, 449. 6th edition.
2. David J.S. and Thomas J.C. "Airway management" An aesthesia. 1994; 42: 1429 – 30.
3. Morgan G.E., Jr M.D. and Mikhail M.S. "Clinical anesthesiology". 2013; 55, 57, 68. 2nd edition.
4. Atkinson R.S., Rushma G.B. and Al fred J. "Lees a synopsis of an aesthesia". 13th edition 2005.
5. Atkinson R.S., Rushma G.B. and Davies N.J.H. "lees synopsis of an aesthesia". 11th edition 1993.
6. Churchill-Davidson H.C. "A practice of an aesthesia". 7th edition 2003.
7. Stoeting R.K., Stephen F. and Dierdorf F. "An aesthesia and co-existing disease". 6th edition 2012.
8. Abou-Madi M., Keszier H. and Yacoub O. "A method for prevention of cardiovascular reactions to laryngoscopy and intubation, Canada an aesthesia". Sco. J. 1975; 22(3).
9. Edelist G.R. and Gilbert B. "Myocardial ischemia during non-Cardiac surgery procedures in patients with coronary artery disease". Anesthesiology. 1979; sl: 3937-7.
10. Wright D. "Scott Brown's otolaryngology (Basic Sciences)". 8th edition. 1997
11. Snell R. "Clinical anatomy for medical students". 9th edition 2012.

12. Goth A. "Medical pharmacology, principles and concepts" 12th edition.
13. Henderson J.J. and Nimmo W. "Practical regional an aesthesia". p.6 , 1983.
14. Roscenberg P.H., Heinononen J. and Takasaki M. "Lidocaine concentration in blood after topical an aesthesia of upper respiratory tract". Acta - Anasth. 1980.
15. Bennett P.N. Aarons LJ, Bending MR, Steiner JA, Rowland M. "Pharmacokinetics of lidocaine and its deethylated metabolite: dose and time dependency studies in man". J. Pharmacokinet Biopharm. 1982; 10(3): 265-281.